Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Galmed Pharmaceuticals (GLMD) generated about n/a in revenue and -$10 million in net income over the trailing twelve months, growing at roughly 108.9% a year. Figures are from SEC filings; this is analysis, not investment advice.
Galmed Pharmaceuticals reported about -$10 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
Galmed Pharmaceuticals's revenue has compounded at roughly 108.9% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside GLMD's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-K filed 31 Mar 2026, covering the period ending 31 Dec 2025, as reported to the SEC. Data last refreshed 17 Apr 2026. How this is calculated.
Fiscal year ends Dec.